On May 15, 2020, Peijia Medical (9996.HK), part of the mother fund portfolio managed by Yuanhe Chukun, successfully launched its IPO, becoming the first high-end medical device company to list on the Hong Kong Stock Exchange in 2020.

Peijia Medical Limited, established in 2012 and headquartered in Suzhou Industrial Park, has been deeply rooted in China’s rapidly growing fields of transcatheter valve therapy and neurointervention for many years. The company has built a collaborative platform that seamlessly integrates R&D, manufacturing, and commercialization capabilities, now boasting a comprehensive "heart-and-brain dual-target" product portfolio. Guided by a commitment to respecting life and driving innovation, Peijia Medical is dedicated to pioneering interventional treatments for cardiovascular and cerebrovascular diseases in China—and ultimately becoming a global medical device leader with Chinese origins.

The Eli Lilly Phase III RMB Fund, backed by Yuanhe Bingsheng Mother Fund, participated in Peijia Medical's Series C financing round in 2017. Co-investors included well-known institutions such as Hillhouse Capital and China Development Fund.